AA
MRNA icon

Addison Advisors’s Moderna MRNA Stock Holding History

Addison Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-12
Closed -$610 – 886
2026
Q1 		$610 Hold
12
– – ﹤0.01% 917
2025
Q4 		$354 Hold
12
– – ﹤0.01% 871
2025
Q3 		$310 Hold
12
– – ﹤0.01% 864
2025
Q2 		$332 Hold
12
– – ﹤0.01% 852
2025
Q1 		$341 Sell
12
-13
-52% -$461 ﹤0.01% 810
2024
Q4 		$1.04K Hold
25
– – ﹤0.01% 785
2024
Q3 		$1.67K Sell
25
-25
-50% -$2.29K ﹤0.01% 748
2024
Q2 		$5.94K Hold
50
– – ﹤0.01% 614
2024
Q1 		$5.33K Hold
50
– – ﹤0.01% 562
2023
Q4 		$4.97K Hold
50
– – ﹤0.01% 573
2023
Q3 		$5.17K Hold
50
– – ﹤0.01% 542
2023
Q2 		$6.08K Sell
50
-69
-58% -$9.21K ﹤0.01% 520
2023
Q1 		$18.3K Sell
119
-3
-2% -$495 0.01% 408
2022
Q4 		$21.9K Sell
122
-3
-2% -$491 0.01% 368
2022
Q3 		$15K Hold
125
– – 0.01% 391
2022
Q2 		$18K Buy
125
+6
+5% +$858 0.01% 369
2022
Q1 		$20K Sell
119
-49
-29% -$8.25K 0.01% 395
2021
Q4 		$43K Buy
+168
New +$49.1K 0.03% 259

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Addison Advisors's MRNA Position: Q2 2026 in Review

Addison Advisors sold out of Moderna (MRNA) in Q2 2026, closing a stake of 12 shares — an estimated $610 sold.

Addison Advisors first reported a position in MRNA in Q4 2021 and held it in 18 quarters. The position peaked at $43K in Q4 2021. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Addison Advisors reported no remaining Moderna position as of Q2 2026 after selling out during the quarter.
  • Addison Advisors sold 12 Moderna shares in Q2 2026, an estimated $610.
  • Addison Advisors first reported a position in Moderna in Q4 2021 and held it in 18 quarters.
  • Addison Advisors's Moderna position peaked at $43K in Q4 2021.
  • 782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Addison Advisors's 13F filing for Q2 2026, filed 10 Aug 2026.